By Stephen Nakrosis
Pharmaceutical company Novartis said it plans to expand U.S.-based manufacturing and research and development, with a total investment of $23 billion over the next five years.
The company said it is planning to increase its R&D activity with a new $1.1 billion research hub in the San Diego area, its second in the U.S. The new complex is expected to open between 2028 and 2029.
Novartis also intends to build four new manufacturing facilities, including 3 which will make biologics drug substances, drug products, device assembly and packaging. The other facility will make chemical drug substances, oral solids dosage forms and packaging. The new manufacturing capacity will enable Novartis to produce 100% of its key medicines end-to-end in the U.S., according to the company.
The company also plans to construct a pair of radioligand therapy manufacturing facilities in Florida and Texas, and expand three RLT manufacturing facilities in Indianapolis, Millburn, NJ, and Carlsbad, CA.
The investments will give Novartis manufacturing capacity in the U.S. for all its core technology platforms, including small molecules and biologics, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 10, 2025 14:29 ET (18:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。